Eupraxia Secures $63.2M to Advance Novel GI Disease Treatments

VICTORIA, British Columbia – February 20, 2026 – Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) (TSX:EPRX) has successfully closed a significant public offering, securing approximately US$63.2 million in gross proceeds. The capital infusion, bolstered by robust investor demand that led to the full exercise of the underwriters' option to purchase additional shares, is set to propel the clinical-stage biotechnology company’s ambitious plans to tackle challenging gastrointestinal (GI) diseases. This financing provides a critical runway for advancing its lead drug candidate, EP-104GI, and expanding the applications of its proprietary Diffusphere™ drug delivery technology.

The successful offering is a powerful vote of confidence from the market, enabling the company to accelerate its clinical programs and move closer to commercial readiness. The funds are earmarked for a multi-pronged strategy focused on bringing innovative, locally delivered treatments to patients with high unmet medical needs.

A Major Financial Boost for a Promising Pipeline

The financing, managed by joint book-runners Cantor and LifeSci Capital, with Bloom Burton and Craig-Hallum as co-managers, was significantly upsized from its initial announcement of US$55 million. The final offering consisted of 7,607,145 common shares priced at US$7.00 per share, alongside 1,428,571 pre-funded warrants. The full exercise of the underwriter's option to purchase an additional 1,178,571 common shares underscores the strong institutional interest in Eupraxia's vision and technology.

While the offering price represented a discount to the company's recent trading levels—a common practice to attract large investors—the market's ultimate reaction was positive. After an initial dip in premarket trading following the pricing announcement, Eupraxia’s shares (EPRX) rallied 4.7% upon the closing of the upsized offering, pushing its market capitalization to approximately US$481 million. This response suggests that investors view the strategic value of the capital raise and the potential for future growth as outweighing the short-term dilution.

“We are pleased to complete this financing, allowing us to significantly expand our pipeline, reach several additional development milestones with EP-104GI for eosinophilic esophagitis, and make meaningful progress towards commercial readiness,” said James Helliwell, CEO of Eupraxia, in the company's official announcement. “We appreciate the support from both existing and new investors as we execute our mission and pursue the next phase of growth for Eupraxia.”

Targeting a Critical Unmet Need in Gastroenterology

The primary beneficiary of this new funding will be EP-104GI, Eupraxia's lead candidate for the treatment of Eosinophilic Esophagitis (EoE). EoE is a chronic, immune-mediated inflammatory disease of the esophagus that can cause severe difficulty swallowing, food impaction, and significant discomfort, impacting a patient's quality of life. It represents a significant and growing unmet medical need with limited long-term treatment options.

Investor confidence has been partly fueled by promising clinical results. The company recently reported positive tissue health data from its ongoing RESOLVE trial, which demonstrated near-complete histological improvement in biopsies taken from patients treated with EP-104GI. This encouraging data suggests the drug candidate has the potential to effectively manage the underlying inflammation characteristic of the disease.

The proceeds will directly fund the next critical stages of EP-104GI's development, including the completion of ongoing preclinical work, the execution of Phase 2 clinical trials, and extensive preparations for a pivotal Phase 3 trial. The funding also covers the necessary regulatory submissions and manufacturing activities required to bring a new therapeutic to market, signaling a clear and funded path toward potential commercialization.

The Power of the Diffusphere™ Platform

Beyond its lead candidate, the financing is a major validation of Eupraxia’s core technology: the proprietary Diffusphere™ platform. This innovative, polymer-based microsphere technology is engineered to provide localized, controlled, and extended delivery of therapeutic agents directly to the site of disease. This approach aims to maximize efficacy while minimizing systemic side effects, a common challenge with conventional drug formulations.

This capital raise enables Eupraxia to demonstrate the broader potential of Diffusphere™ as a versatile platform technology. A portion of the proceeds will be used to accelerate and expand clinical studies of EP-104GI into other difficult-to-treat GI indications. The company has identified esophageal strictures and fibrostenotic Crohn’s disease as key expansion targets—conditions characterized by scarring and narrowing of the GI tract that present significant treatment challenges.

By pursuing these additional indications, Eupraxia is not only diversifying its pipeline but also building a compelling case for Diffusphere™ as a foundational technology for a new class of locally-acting, extended-release therapies. The funds will also support research and development of entirely new pipeline candidates, further leveraging the platform's capabilities to address other areas of high unmet medical need.

Wall Street Signals Strong Confidence

The financial markets and analyst community have responded with notable optimism, viewing the successful offering as a de-risking event that provides a clear financial runway into 2028. Following the news, several investment banks reaffirmed their positive outlook on the company.

Cantor Fitzgerald raised its price target on Eupraxia's stock from US$11.00 to US$19.00, maintaining an 'Overweight' rating. Similarly, Raymond James resumed its coverage with a 'Strong Buy' rating and an US$18.00 price target. These upward revisions reflect a belief in the company's clinical strategy, the market potential of EP-104GI, and the long-term value of the Diffusphere™ platform.

With a fortified balance sheet, a clear development path for its lead asset, and a strategy to expand its technological footprint, Eupraxia is now in a strong position to execute on its clinical and commercial goals. The bullish price targets from influential analysts underscore a growing consensus that Eupraxia's strategy and technology platform are well-positioned for significant milestones ahead.